The significance of tumor heterogeneity for prediction of DNA ploidy of prostate cancer

Scandinavian Journal of Urology and Nephrology

Volumn 39, Issue 5, 2005, Pages 387-392

  Häggarth, Lars ^a   Auer, Gert ^b   Busch, Christer ^c   Norberg, Mona ^c   Häggman, Michael ^c   Egevad, Lars ^b,d  

^a ST GÖRAN S HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

DNA ploidy; Needle biopsies; Pathology; Prostatectomy; Prostatic neoplasms

Indexed keywords

ANEUPLOIDY; ARTICLE; CANCER INVASION; CANCER SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DIPLOIDY; FLOW CYTOMETRY; GENE MAPPING; GENETIC HETEROGENEITY; HISTOGRAM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PLOIDY; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATECTOMY; SEMINAL VESICLE; TETRAPLOIDY; TISSUE SECTION;

AGED; BIOPSY, NEEDLE; DIPLOIDY; DNA, NEOPLASM; GENETIC HETEROGENEITY; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 27944491292     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/00365590500239883     Document Type: Article

References (33)

1. Berner A, Waere H, Nesland JM, Paus E, Danielsen HE, Fossa SD. DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma. Br J Urol 1995;75:26-32.
2. Epstein JI, Pizov G, Steinberg GD, Carter HB, Pitcock R, Armas OA, et al. Correlation of prostate cancer nuclear deoxyribonucleic acid, size, shape and Gleason grade with pathological stage at radical prostatectomy. J Urol 1992;148: 87-91.
3. Sebo TJ, Cheville JC, Riehle DL, Lohse CM, Pankratz VS, Myers RP, et al. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases. Cancer 2001;91:2196-204.
4. Lorenzato M, Rey D, Durlach A, Bouttens D, Birembaut P, Staerman F. DNA image cytometry on biopsies can help the detection of localized Gleason 3 + 3 prostate cancers. J Urol 2004;172:1311-3.
5. Carmichael MJ, Veltri RW, Partin AW, Miller MC, Walsh PC, Epstein JI. Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J Urol 1995;153:1015-9.
6. Forsslund G, Esposti PL, Nilsson B, Zetterberg A. The prognostic significance of nuclear DNA content in prostatic carcinoma. Cancer 1992;69:1432-9.
7. Montgomery BT, Nativ O, Blute ML, Farrow GM, Myers RP, Zincke H, et al. Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis. Arch Surg 1990; 125:327-31.
8. Schroder F, Tribukait B, Bocking A, DeVere-White R, Koss L, Lieber M, et al. Clinical utility of cellular DNA measurements in prostate carcinoma. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. Scand J Urol Nephrol Suppl 1994;162:51-63.
9. Tribukait B. DNA flow cytometry in carcinoma of the prostate for diagnosis, prognosis and study of tumor biology. Acta Oncol 1991;30:187-92.
10. Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol 2002;167:117-22.
11. Lerner SE, Blute ML, Zincke H. Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Semin Urol Oncol 1996;14:12-20.
12. Adolfsson J. Prognostic value of deoxyribonucleic acid content in prostate cancer: a review of current results. Int J Cancer 1994;58:211-6.
13. Humphrey PA, Walther PJ, Currin SM, Vollmer RT. Histologic grade, DNA ploidy, and intraglandular tumor extent as indicators of tumor progression of clinical stage B prostatic carcinoma. A direct comparison. Am J Surg Pathol 1991;15:1165-70.
14. Lundberg S, Carstensen J, Rundquist I. DNA flow cytometry and histopathological grading of paraffin-embedded prostate biopsy specimens in a survival study. Cancer Res 1987;47:1973-7.
15. Kucuk O, Demirer T, Gilman-Sachs A, Taw I, Mangold M, Singh S, et al. Intratumor heterogeneity of DNA ploidy and correlations with clinical stage and histologic grade in prostate cancer. J Surg Oncol 1993;54:171-4.
16. O'Malley FP, Grignon DJ, Keeney M, Kerkvliet N, McLean C. DNA heterogeneity in prostatic adenocarcinoma. A DNA flow cytometric mapping study with whole organ sections of prostate. Cancer 1993;71:2797-802.
17. Sassi I, Mangili F, Sanvito F, Andreassi A, Cantaboni A. Reproducibility of FCM-DNA ploidy analysis in prostatic cancer: comparison between needle biopsy and surgical specimens. Anal Cell Pathol 1993;5:17-21.
18. Häggman M, de la Torre M, Norberg M, Busch C. Preoperative histological and cytological diagnosis and DNA ploidy assessment of localized prostatic cancer. A comparison between findings in biopsies and total prostatectomy specimens. APMIS 1994;102:841-8.
19. Warzynski MJ, Soechtig CE, Maatman TJ, Goldsmith LC, Grobbel MA, Carothers GG, et al. DNA heterogeneity determined by flow cytometry in prostatic adenocarcinoma-necessitating multiple site analysis. Prostate 1995;27:329-35.
20. Egevad L, Engström K, Mattson S, Wester K, Busch C. Heterogeneity of DNA ploidy in prostate cancer. J Urol Pathol 1999;10:23-37.
21. Steinbeck RG, Auer GU, Zetterberg AD. Reliability and significance of DNA measurements in interphase nuclei and division figures in histological sections. Eur J Cancer 1999; 35:787-95.
22. Partin AW, Epstein JI, Cho KR, Gittelsohn AM, Walsh PC. Morphometric measurement of tumor volume and per cent of gland involvement as predictors of pathological stage in clinical stage B prostate cancer. J Urol 1989;141:341-5.
23. Vindeløv LL, Christensen IJ, Nissen NI. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983;3:323-7.
24. Jones EC, McNeal J, Bruchovsky N, de-Jong G. DNA content in prostatic adenocarcinoma. A flow cytometry study of the predictive value of aneuploidy for tumor volume, percentage Gleason grade 4 and 5, and lymph node metastases. Cancer 1990;66:752-7.
25. Greene DR, Taylor SR, Wheeler TM, Scardino PT. DNA ploidy by image analysis of individual foci of prostate cancer: a preliminary report. Cancer Res 1991;51:4084-9.
26. Horninger W, Berger AP, Rogatsch H, Gschwendtner A, Steiner H, Niescher M, et al. Characteristics of prostate cancers detected at low PSA levels. Prostate 2004;58:232-7.
27. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection. J Urol 2002;168:509-13.
28. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Prognostic value of the Gleason score in prostate cancer. BJU Int 2002;89:538-42.
29. McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 1990;66:1225-33.
30. Pan CC, Potter SR, Partin AW, Epstein JI. The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. Am J Surg Pathol 2000;24:563-9.
31. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999;281:1395-400.
32. Pindur A, Chakraborty S, Welch DG, Wheeler TM. DNA ploidy measurements in prostate cancer: differences between image analysis and flow cytometry and clinical implications. Prostate 1994;25:189-98.
33. Falkmer UG. Methodologic sources of errors in image and flow cytometric DNA assessments of the malignancy potential of prostatic carcinoma. Hum Pathol 1992;23: 360-7.